Abstract
Atrial fibrillation is the most common clinically significant cardiac arrhythmia and is associated with markedly increased risks of cardiovascular diseases. Atrial fibrillation and hypertension often coexist and are both responsible for considerable morbidity and mortality. Aggressive treatment of hypertension, especially with a blocker of the reninangiotensin system, may postpone or prevent development of atrial fibrillation and reduce thromboembolic complications. Awareness of the risk of developing atrial fibrillation in hypertensives may be of great importance and focus on prevention of atrial fibrillation development with optimal antihypertensive treatment may reduce morbidity, mortality and health care expenditures.
Keywords: Angiotensin-converting enzyme inhibitors, angiotensin II type I receptor blockers, atrial fibrillation, hypertension, renin-angiotensin system, cardiac arrhythmia, cardiovascular diseases, thromboembolic complications, Framingham Heart Study, systolic blood pressure, electrocardiogram, ANTIHYPERTEN-SIVE TREATMENT, RAS-blockade, cardiac hypertrophy, left ventricular hypertrophy, beta-blocker, valsartan, calcium channel blockers, (lisinopril), (doxazosin), (chlorthalidone), (losartan), (amlodipine), atenolol/amlodipine, telmisartan, ESH/ESC guidelines, anti-arrhythmic drugs, (ramipril), (irbesartan), myocardial infarction, diltiazem, Diuretics, hydrochlorothiazide, Alpha-Adrenoreceptor Blocker
Current Vascular Pharmacology
Title: A Link Between Hypertension and Atrial Fibrillation: Methods of Treatment and Prevention
Volume: 8 Issue: 6
Author(s): Tonje A. Aksnes and Sverre E. Kjeldsen
Affiliation:
Keywords: Angiotensin-converting enzyme inhibitors, angiotensin II type I receptor blockers, atrial fibrillation, hypertension, renin-angiotensin system, cardiac arrhythmia, cardiovascular diseases, thromboembolic complications, Framingham Heart Study, systolic blood pressure, electrocardiogram, ANTIHYPERTEN-SIVE TREATMENT, RAS-blockade, cardiac hypertrophy, left ventricular hypertrophy, beta-blocker, valsartan, calcium channel blockers, (lisinopril), (doxazosin), (chlorthalidone), (losartan), (amlodipine), atenolol/amlodipine, telmisartan, ESH/ESC guidelines, anti-arrhythmic drugs, (ramipril), (irbesartan), myocardial infarction, diltiazem, Diuretics, hydrochlorothiazide, Alpha-Adrenoreceptor Blocker
Abstract: Atrial fibrillation is the most common clinically significant cardiac arrhythmia and is associated with markedly increased risks of cardiovascular diseases. Atrial fibrillation and hypertension often coexist and are both responsible for considerable morbidity and mortality. Aggressive treatment of hypertension, especially with a blocker of the reninangiotensin system, may postpone or prevent development of atrial fibrillation and reduce thromboembolic complications. Awareness of the risk of developing atrial fibrillation in hypertensives may be of great importance and focus on prevention of atrial fibrillation development with optimal antihypertensive treatment may reduce morbidity, mortality and health care expenditures.
Export Options
About this article
Cite this article as:
A. Aksnes Tonje and E. Kjeldsen Sverre, A Link Between Hypertension and Atrial Fibrillation: Methods of Treatment and Prevention, Current Vascular Pharmacology 2010; 8 (6) . https://dx.doi.org/10.2174/157016110793563807
DOI https://dx.doi.org/10.2174/157016110793563807 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Polyphenols: Potential Use in the Prevention and Treatment of Cardiovascular Diseases
Current Pharmaceutical Design Nebulizer Therapy in Pulmonology: Review of the Literature
Current Respiratory Medicine Reviews Coenzyme Q10 Reduction with Statins: Another Pleiotropic Effect
Current Drug Therapy Diabetic Vasculopathy and the Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 (LOX-1)
Current Diabetes Reviews Sepsis-induced Cardiomyopathy
Current Cardiology Reviews Alzheimer’s Disease and Retinal Degeneration: A Glimpse at Essential Trace Metals in Ocular Fluids and Tissues
Current Alzheimer Research Gestational Diabetes Mellitus Pharmacological Prevention and Treatment
Current Pharmaceutical Design Nitric Oxide as a Marker for Levo-Thyroxine Therapy in Subclinical Hypothyroid Patients
Current Vascular Pharmacology Investigation of Gene Expression Pattern of 5HTR2a and MAO-A in PBMCs of Individuals Who Had Been Exposed to Air Pollution in Highly Polluted Area
Recent Patents on Inflammation & Allergy Drug Discovery Refractory Cough as a Remote Manifestation of Retroperitoneal Liposarcoma
Current Cancer Therapy Reviews Development and Clinical use of Prasugrel and Ticagrelor
Current Pharmaceutical Design The Renal Outer Medullary Potassium Channel (ROMK): An Intriguing Pharmacological Target for an Innovative Class of Diuretic Drugs
Current Medicinal Chemistry Kinins and Cardiovascular Diseases
Current Pharmaceutical Design The Modification of Serum Lipids after Acute Coronary Syndrome and Importance in Clinical Practice
Current Cardiology Reviews Methylation Profile of miR-9-1 and miR-9-1/-9-3 as Potential Biomarkers of Diabetic Retinopathy
Current Diabetes Reviews Depression Rises the Risk of Hypertension Incidence: Discussing the Link through the Ca2+/cAMP Signalling
Current Hypertension Reviews Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine
Current Pharmacogenomics and Personalized Medicine Microalgal Fatty Acids and Their Implication in Health and Disease
Mini-Reviews in Medicinal Chemistry Aquaporin and Vascular Diseases
Current Neuropharmacology Cyclophilin A: A Predictive Biomarker of Carotid Stenosis in Cerebral Ischemic Stroke
Current Neurovascular Research